作者
Hung Huynh, Huai-Xiang Hao, Stephen L Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David Yang, David Ruddy, Manway Liu, Adnan Derti, Marissa N Balak, Michael R Palmer, Yan Wang, Benjamin H Lee, Dalila Sellami, Andrew X Zhu, Robert Schlegel, Alan Huang
发表日期
2015/5/1
期刊
Molecular cancer therapeutics
卷号
14
期号
5
页码范围
1224-1235
出版商
American Association for Cancer Research
简介
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and hyperactivation of mTOR signaling plays a pivotal role in HCC tumorigenesis. Tuberous sclerosis complex (TSC), a heterodimer of TSC1 and TSC2, functions as a negative regulator of mTOR signaling. In the current study, we discovered that TSC2 loss-of-function is common in HCC. TSC2 loss was found in 4 of 8 HCC cell lines and 8 of 28 (28.6%) patient-derived HCC xenografts. TSC2 mutations and deletions are likely to be the underlying cause of TSC2 loss in HCC cell lines, xenografts, and primary tumors for most cases. We further demonstrated that TSC2-null HCC cell lines and xenografts had elevated mTOR signaling and, more importantly, were significantly more sensitive to RAD001/everolimus, an mTORC1 inhibitor. These preclinical findings led to the analysis of TSC2 status in HCC samples collected in the …
引用总数
20152016201720182019202020212022202320242181621154132132